BACKGROUND Scintimammography using Tc-99m MIBI (SMM) is often used clinically as a second line diagnostic test for the detection of breast cancer in cases where there is concern about the results of x-ray mammography (XMM) and ultrasound. Both of these methods, but particularly XMM, may miss a significant proportion of ductal carcinoma in situ (DCIS). MATERIAL AND METHODS This study was perfo...

We describe a preclinical model that investigates progression of early-stage ductal carcinoma in situ (DCIS) and report that compromised myoepithelial cell differentiation occurs before transition to invasive disease. Human breast cancer MCF10DCIS.com cells were delivered into the mouse mammary teat by intraductal injection in the absence of surgical manipulations and accompanying wound-healing...

BACKGROUND In the absence of definitive data about the natural history of DCIS the appropriateness of describing DCIS as cancer is controversial. METHODS We conducted a survey amongst British Breast Group (BBG) members, to determine which descriptions of DCIS were deemed most accurate and appropriate. RESULTS 54/73 (74%) attendees completed the survey: A majority (34/54; 63%) said they woul...

The spread of mammographic screening programmes around the world, including in developing countries, has substantially contributed to the diagnosis of small non-palpable lesions, which has increased the detection rate of DCIS (ductal carcinoma in situ). DCIS is heterogeneous in several ways, such as its clinical presentation, morphology and genomic profile. Excellent outcomes have been reported...

Background The incidence of detected ductal carcinoma in situ (DCIS) continues to increase and now accounts for 14% all breast cancer, 20%-25% screen-detected cases. Treatment trends DCIS are important order inform the ongoing debate about possible overdiagnosis overtreatment, but have not been investigated over a decade Australia New Zealand. Against this background, we aimed describe temporal...

Background: Considering highly selected patients with ductal carcinoma in situ (DCIS), active surveillance is a valid alternative to surgery. Our study aimed show the reliability of post-biopsy complete lesion removal, documented by mammogram, as additional criterion select these patients. Methods: A total 2173 vacuum-assisted breast biopsies (VABBs) DCIS were reviewed. Surgery was performed al...

Wouldn't it be easier if we lived in a binary world? Everything would be either black or white, yes or no, 1 or 0. And biopsy results would be either normal or cancer. Unfortunately, in the world of cancer, our efforts to detect the disease early have made this a fantasy. We are increasingly faced with the reality of a big gray zone — a broad spectrum of pathologic fi ndings between normal tiss...

Ductal carcinoma in situ (DCIS) of the breast is becoming one of the most important diseases diagnosed in preventive medicine screening. The current age-adjusted incidence rate of DCIS is 32.5 per 100,000 women. For women 50–64 years of age, the incidence is approximately 88 per 100,000. Currently, for every 4 diagnoses of invasive breast cancer, there is 1 diagnosis of DCIS. Risk of DCIS is ra...

Adjuvant antiestrogen (AE) therapy has been proposed for all women with ductal carcinoma in situ (DCIS). However, many cases of DCIS are of the high-grade, estrogen receptor (ER)-negative subtype that are unlikely to respond to AE treatment. Hormonal agents work by increasing apoptosis and/or decreasing cell proliferation; therefore, we studied the effect of a pure AE on levels of apoptosis and...

PURPOSE The purpose of this study is to determine relative accuracy of mammography (MMG), ultrasonography (US), and magnetic resonance imaging (MRI) in patients with ductal carcinoma in situ (DCIS) as compared with pathology finding. METHOD AND MATERIALS Institutional review board approval was obtained with waiver of informed consent. Between January 2001 and December 2008, 91 women with 97 les...